Anemia News and Research

RSS
Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.
Pazopanib demonstrates clinically meaningful activity in patients with refractory urothelial cancer

Pazopanib demonstrates clinically meaningful activity in patients with refractory urothelial cancer

Federal Court refuses to reconsider bone marrow donor payments

Federal Court refuses to reconsider bone marrow donor payments

Change in registry protocols leads to underreporting of myeloid malignancies

Change in registry protocols leads to underreporting of myeloid malignancies

FDA approves Omontys - new anemia drug for chronic kidney disease patients

FDA approves Omontys - new anemia drug for chronic kidney disease patients

First Edition: March 28, 2012

First Edition: March 28, 2012

New gene transfer technique can treat beta-thalassemia, sickle cell anemia

New gene transfer technique can treat beta-thalassemia, sickle cell anemia

Medgenics to commence EPODURE Biopumps Phase IIa study in ESRD-related anemia

Medgenics to commence EPODURE Biopumps Phase IIa study in ESRD-related anemia

Aternative pain medication without narcotics safe after sinus surgery

Aternative pain medication without narcotics safe after sinus surgery

New perspective on why the immune system makes us worse while trying to make us well

New perspective on why the immune system makes us worse while trying to make us well

XTL Biopharmaceuticals completes $2.4 million private placement of securities

XTL Biopharmaceuticals completes $2.4 million private placement of securities

Alnylam commences dosing in ALN-TTR02 Phase I clinical trial for TTR-mediated amyloidosis

Alnylam commences dosing in ALN-TTR02 Phase I clinical trial for TTR-mediated amyloidosis

Shire enters agreement to acquire FerroKin BioSciences

Shire enters agreement to acquire FerroKin BioSciences

Watson commences Esmya Phase 3 trial in women with anemia linked to uterine leiomyomas

Watson commences Esmya Phase 3 trial in women with anemia linked to uterine leiomyomas

3SBio fourth quarter total net revenues increase 38.2% to RMB139.9M

3SBio fourth quarter total net revenues increase 38.2% to RMB139.9M

3SBio, DaVita partner to offer dialysis services in NE China

3SBio, DaVita partner to offer dialysis services in NE China

Fera introduces Sulfacetamide Ointment for conjunctivitis

Fera introduces Sulfacetamide Ointment for conjunctivitis

FDA issues Complete Response Letter to Eisai for Dacogen sNDA

FDA issues Complete Response Letter to Eisai for Dacogen sNDA

AMAG fourth quarter total revenues decrease to $14.9 million

AMAG fourth quarter total revenues decrease to $14.9 million

Ruxolitinib boosts QOL and survival for patients with myelofibrosis

Ruxolitinib boosts QOL and survival for patients with myelofibrosis

NEJM publishes results from two Jakafi Phase III studies on MF

NEJM publishes results from two Jakafi Phase III studies on MF

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.